hydralazine has been researched along with Cardiovascular Stroke in 65 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 9.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "The hemodynamic effect of venous dilatation (intravenous isosorbide dinitrate [ISDN]) and arteriolar dilatation (intravenous hydralazine), both as firstline treatment and then combined with intravenous furosemide, were evaluated in a randomized, between-group comparison in 20 men with severe acute left-sided cardiac failure after myocardial infarction (MI)." | 9.05 | Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction. ( Forsyth, DR; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1983) |
| " Because aldosterone production in the heart increases after myocardial infarction (MI), we investigated the effect of chronic administration of spironolactone, an aldosterone receptor antagonist, in rats after MI compared with the effects produced by losartan and hydralazine." | 7.72 | Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. ( de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG, 2003) |
| " In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics." | 7.70 | Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. ( El Salibi, E; Nguyen, T; Rouleau, JL, 1998) |
| "In rats with large myocardial infarctions, we compared the effects of captopril, a presumed arterial and venous vasodilator, with hydralazine, which is thought primarily to be an arterial vasodilator." | 7.67 | Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. ( Aguirre, M; Gay, RG; Goldman, S; Raya, TE, 1989) |
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 5.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "A prospective randomised trial compared the immediate haemodynamic effects of intravenous diuretic (frusemide), venodilator (isosorbide dinitrate), arteriolar dilator (hydralazine), and positive inotropic stimulation (prenalterol) as first-line therapy for acute left ventricular (LV) failure following myocardial infarction." | 5.06 | First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. ( Hussain, M; Nelson, GI; Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP, 1987) |
| "The hemodynamic effect of venous dilatation (intravenous isosorbide dinitrate [ISDN]) and arteriolar dilatation (intravenous hydralazine), both as firstline treatment and then combined with intravenous furosemide, were evaluated in a randomized, between-group comparison in 20 men with severe acute left-sided cardiac failure after myocardial infarction (MI)." | 5.05 | Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction. ( Forsyth, DR; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1983) |
| " Some of this information includes: the unexpected yet very real hazards as well as benefits associated with the long-term use of powerful drugs, in particular the original description of hydralazine-induced lupus, its relation to genetic markers and its association with control of hypertension; the apparently decreasing need for antihypertensive drugs in subjects with well-controlled severe and moderate hypertension; the identification of risk factors for the complications of hypertension and the quantitation of their effects; the decrease in the incidence of hypertensive complications associated with the pharmacologic treatment of severe, moderate and, at least, the upper ranges of mild hypertension; the possibility of designing a chemical to block a specific reaction and the realization that it would have broader than expected effects; and the primary prevention of myocardial infarction in very high risk subjects." | 4.77 | The evolution of antihypertensive therapy. ( Perry, HM, 1985) |
| "Although amlodipine, a long-acting L-type calcium channel blocker, reportedly prevents left ventricular remodeling and dysfunction after myocardial infarction, the mechanism responsible is not yet well understood." | 3.74 | Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. ( Aoyama, T; Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kawasaki, M; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Ushikoshi, H, 2007) |
| " Because aldosterone production in the heart increases after myocardial infarction (MI), we investigated the effect of chronic administration of spironolactone, an aldosterone receptor antagonist, in rats after MI compared with the effects produced by losartan and hydralazine." | 3.72 | Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. ( de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG, 2003) |
| " In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics." | 3.70 | Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. ( El Salibi, E; Nguyen, T; Rouleau, JL, 1998) |
| "In rats with large myocardial infarctions, we compared the effects of captopril, a presumed arterial and venous vasodilator, with hydralazine, which is thought primarily to be an arterial vasodilator." | 3.67 | Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. ( Aguirre, M; Gay, RG; Goldman, S; Raya, TE, 1989) |
| " Similarly, chronic congestive heart failure patients, irrespective of the etiology, improve hemodynamically after an infusion of phentolamine, nitroprusside or hydralazine." | 3.66 | Electrophysiologic properties of hydralazine in man. ( Becker, WH; Gould, L; Reddy, CV; Singh, BK; Zen, B, 1980) |
| "The long-term effects of vasodilator therapy with oral hydralazine and long-acting nitrates were studied in 34 patients with refractory heart failure." | 3.66 | Results of long-term vasodilator therapy in patients with refractory congestive heart failure. ( Greenberg, BH; Walsh, WF, 1981) |
| "Pre-treatment with hydralazine was shown to inhibit both mitochondrial fission and mitochondrial membrane depolarisation induced by oxidative stress in HeLa cells." | 1.72 | Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. ( Chinda, K; Costa, JRSD; Crespo-Avilan, GE; Hausenloy, DJ; Hernandez-Resendiz, S; Holien, JK; Kalkhoran, SB; Ketteler, R; Kriston-Vizi, J; Lees, JG; Lim, SY; Ling, NXY; Riquelme, JA; Rosdah, AA; Samangouei, P; Yap, EP; Yellon, DM, 2022) |
| "Hydralazine is an FDA-approved antihypertensive agent which has been utilized for years either alone or in combination with other medications especially the beta-blockers." | 1.51 | Electrocardiographic Changes Following Acute Hydralazine Overdose. ( Ahrari, Y; Akbari-Rad, M; Eshraghi, A; Esmaeili, A; Firoozi, A; Vahabzadeh, M, 2019) |
| " Independent of their hemodynamic effects, a chronic use of either ET(A) or ET(A)/ET(B) antagonists may modify the arrhythmogenic response to programmed electrical stimulation." | 1.35 | Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats. ( Chang, NC; Chen, CC; Lee, TM; Lin, MS, 2008) |
| "Left ventricular remodeling was profoundly changed by statin treatment." | 1.31 | Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. ( Bauer, WR; Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Haase, A; Hiller, KH; Hu, K; Nahrendorf, M; Schweizer, G, 2002) |
| "Treatment with hydralazine did not reduce infarct size [59." | 1.29 | Effect of bimakalim (EMD 52692), an opener of ATP sensitive potassium channels, on infarct size, coronary blood flow, regional wall function, and oxygen consumption in swine. ( Becker, KH; Häusler, G; Lues, I; Rohmann, S; Schelling, P; Soei, LK; Verdouw, PD; Weygandt, H, 1994) |
| "Treated hypertension is a weak risk factor for acute myocardial infarction in unselected hypertensive patients." | 1.29 | Acute myocardial infarction in patients treated for hypertension in the Skaraborg Hypertension Project. ( Lindblad, U; Ranstam, J; Råstam, L, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (64.62) | 18.7374 |
| 1990's | 10 (15.38) | 18.2507 |
| 2000's | 8 (12.31) | 29.6817 |
| 2010's | 2 (3.08) | 24.3611 |
| 2020's | 3 (4.62) | 2.80 |
| Authors | Studies |
|---|---|
| Wiggers, H | 1 |
| Køber, L | 1 |
| Gislason, G | 1 |
| Schou, M | 1 |
| Poulsen, MK | 1 |
| Vraa, S | 1 |
| Nielsen, OW | 1 |
| Bruun, NE | 1 |
| Nørrelund, H | 1 |
| Hollingdal, M | 1 |
| Barasa, A | 1 |
| Bøttcher, M | 1 |
| Dodt, K | 1 |
| Hansen, VB | 1 |
| Nielsen, G | 1 |
| Knudsen, AS | 1 |
| Lomholdt, J | 1 |
| Mikkelsen, KV | 1 |
| Jonczy, B | 1 |
| Brønnum-Schou, J | 1 |
| Poenaru, MP | 1 |
| Abdulla, J | 1 |
| Raymond, I | 1 |
| Mahboubi, K | 1 |
| Sillesen, K | 1 |
| Serup-Hansen, K | 1 |
| Madsen, JS | 1 |
| Kristensen, SL | 1 |
| Larsen, AH | 1 |
| Bøtker, HE | 1 |
| Torp-Petersen, C | 1 |
| Eiskjær, H | 1 |
| Møller, J | 1 |
| Hassager, C | 1 |
| Steffensen, FH | 1 |
| Bibby, BM | 1 |
| Refsgaard, J | 1 |
| Høfsten, DE | 1 |
| Mellemkjær, S | 1 |
| Gustafsson, F | 1 |
| Kalkhoran, SB | 1 |
| Kriston-Vizi, J | 1 |
| Hernandez-Resendiz, S | 1 |
| Crespo-Avilan, GE | 1 |
| Rosdah, AA | 1 |
| Lees, JG | 1 |
| Costa, JRSD | 1 |
| Ling, NXY | 1 |
| Holien, JK | 1 |
| Samangouei, P | 1 |
| Chinda, K | 1 |
| Yap, EP | 1 |
| Riquelme, JA | 1 |
| Ketteler, R | 1 |
| Yellon, DM | 1 |
| Lim, SY | 1 |
| Hausenloy, DJ | 1 |
| Robson, A | 1 |
| Vahabzadeh, M | 1 |
| Eshraghi, A | 1 |
| Akbari-Rad, M | 1 |
| Firoozi, A | 1 |
| Esmaeili, A | 1 |
| Ahrari, Y | 1 |
| Yang, W | 1 |
| Li, H | 1 |
| Luo, H | 1 |
| Luo, W | 1 |
| Nahrendorf, M | 1 |
| Hu, K | 1 |
| Hiller, KH | 1 |
| Galuppo, P | 1 |
| Fraccarollo, D | 1 |
| Schweizer, G | 1 |
| Haase, A | 1 |
| Ertl, G | 1 |
| Bauer, WR | 1 |
| Bauersachs, J | 1 |
| WERKOE, L | 1 |
| Mill, JG | 2 |
| Milanez, Mda C | 1 |
| de Resende, MM | 1 |
| Gomes, Mda G | 1 |
| Leite, CM | 2 |
| Dikow, R | 1 |
| Kihm, LP | 1 |
| Zeier, M | 1 |
| Kapitza, J | 1 |
| Törnig, J | 1 |
| Amann, K | 1 |
| Tiefenbacher, C | 1 |
| Ritz, E | 1 |
| Nakanishi, M | 1 |
| Saito, Y | 1 |
| Kishimoto, I | 1 |
| Harada, M | 1 |
| Kuwahara, K | 1 |
| Takahashi, N | 1 |
| Kawakami, R | 1 |
| Nakagawa, Y | 1 |
| Tanimoto, K | 1 |
| Yasuno, S | 1 |
| Usami, S | 1 |
| Li, Y | 2 |
| Adachi, Y | 1 |
| Fukamizu, A | 1 |
| Garbers, DL | 1 |
| Nakao, K | 1 |
| Takemura, G | 2 |
| Okada, H | 2 |
| Miyata, S | 2 |
| Kanamori, H | 2 |
| Maruyama, R | 2 |
| Esaki, M | 2 |
| Li, L | 1 |
| Ogino, A | 2 |
| Ohno, T | 1 |
| Kondo, T | 1 |
| Nakagawa, M | 2 |
| Minatoguchi, S | 2 |
| Fujiwara, T | 2 |
| Fujiwara, H | 2 |
| Aoyama, T | 1 |
| Ushikoshi, H | 1 |
| Kawasaki, M | 1 |
| Lee, TM | 1 |
| Chen, CC | 1 |
| Lin, MS | 1 |
| Chang, NC | 1 |
| Hoenig, MR | 1 |
| Bianchi, C | 1 |
| Sellke, FW | 1 |
| Nelson, GI | 3 |
| Silke, B | 4 |
| Ahuja, RC | 1 |
| Walker, C | 1 |
| Forsyth, DR | 2 |
| Verma, SP | 4 |
| Taylor, SH | 5 |
| Gould, L | 1 |
| Reddy, CV | 1 |
| Zen, B | 1 |
| Singh, BK | 1 |
| Becker, WH | 1 |
| Chatterjee, K | 3 |
| Parmley, WW | 2 |
| Pouleur, H | 2 |
| Engler, RL | 1 |
| Link, J | 2 |
| Printz, MP | 1 |
| Covell, JW | 2 |
| Hussain, M | 2 |
| Khomenko, VL | 1 |
| Pomerantsev, VP | 2 |
| Vasiuk, IuA | 2 |
| Wagner, GC | 1 |
| Robinson, PH | 1 |
| Perry, HM | 2 |
| Ferguson, RK | 1 |
| Vlasses, PH | 1 |
| Koplin, JR | 1 |
| Shirinian, A | 1 |
| Burke, JF | 1 |
| Alexander, JC | 1 |
| Freis, E | 1 |
| Rouleau, JL | 3 |
| Benge, W | 1 |
| Hiramatsu, B | 1 |
| Engler, R | 1 |
| Printz, M | 1 |
| Walsh, WF | 1 |
| Greenberg, BH | 1 |
| Kotler, MN | 1 |
| Segal, BL | 1 |
| Friedlander, RP | 1 |
| Schwartz, MJ | 1 |
| Davies, MJ | 1 |
| Cronin, KD | 1 |
| Gomes, MG | 1 |
| Vassallo, DV | 1 |
| Rohmann, S | 1 |
| Weygandt, H | 1 |
| Schelling, P | 1 |
| Soei, LK | 1 |
| Becker, KH | 1 |
| Verdouw, PD | 1 |
| Lues, I | 1 |
| Häusler, G | 1 |
| Lindblad, U | 1 |
| Råstam, L | 1 |
| Ranstam, J | 1 |
| Ikeda, K | 1 |
| Nara, Y | 1 |
| Tagami, M | 1 |
| Yamori, Y | 1 |
| Nguyen, T | 2 |
| El Salibi, E | 2 |
| Taguchi, T | 1 |
| Uchida, W | 1 |
| Takenaka, T | 1 |
| Takeo, S | 1 |
| Wilhelmsen, L | 1 |
| Berglund, G | 1 |
| Sannerstedt, R | 1 |
| Hansson, L | 1 |
| Andersson, O | 1 |
| Sievertsson, R | 1 |
| Wikstrand, J | 1 |
| Schrey, A | 1 |
| Mason, DT | 2 |
| Massie, BM | 1 |
| Lloyd, EA | 1 |
| Miller, RR | 1 |
| Awan, NA | 1 |
| Francoual, M | 1 |
| Lellouche, D | 1 |
| Castaigne, A | 1 |
| Estampes, B | 1 |
| Vernant, P | 1 |
| Phaneuf, DC | 1 |
| Waters, DD | 1 |
| Théroux, P | 1 |
| Pelletier, G | 1 |
| Mizgala, HF | 1 |
| Diethelm, AG | 1 |
| Hartley, MW | 1 |
| Aldrete, JS | 1 |
| Sterling, WA | 1 |
| Morgan, JM | 1 |
| Taguchi, J | 1 |
| Freis, ED | 3 |
| Reynolds, GW | 2 |
| Kelly, JG | 1 |
| Richmond, A | 2 |
| van Krimpen, C | 2 |
| Smits, JF | 2 |
| Cleutjens, JP | 2 |
| Debets, JJ | 1 |
| Schoemaker, RG | 2 |
| Struyker Boudier, HA | 1 |
| Bosman, FT | 1 |
| Daemen, MJ | 2 |
| Sorkin, EM | 1 |
| Clissold, SP | 1 |
| Brogden, RN | 1 |
| Raya, TE | 1 |
| Gay, RG | 1 |
| Aguirre, M | 1 |
| Goldman, S | 1 |
| Przyklenk, K | 1 |
| Kloner, RA | 1 |
| Franciosa, JA | 1 |
| Fedotenkov, SA | 1 |
| Ruksin, VV | 1 |
| Chasis, H | 1 |
| Evans, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M[NCT03514108] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2018-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for hydralazine and Cardiovascular Stroke
| Article | Year |
|---|---|
Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis.
Topics: Angiogenic Proteins; Animals; Cardiovascular Agents; Cardiovascular Diseases; Cell Hypoxia; Cell Mov | 2008 |
[Peripheral vasodilator agents in cardiology].
Topics: Clinical Trials as Topic; Coronary Vessels; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocar | 1980 |
Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
Topics: Aorta; Cardiac Output; Chronic Disease; Heart; Heart Failure; Heart Ventricles; Hemodynamics; Humans | 1978 |
Vasodilator therapy of pump failure complicating acute myocardial infarction.
Topics: Animals; Blood Pressure; Cardiac Output; Heart Arrest; Heart Rate; Hemodynamics; Humans; Hydralazine | 1979 |
The use of vasodilator agents in the treatment of heart failure.
Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela | 1979 |
Afterload reduction in the management of congestive heart failure following acute myocardial infarction.
Topics: Acute Disease; Dopamine; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Infarction; Ni | 1978 |
[Vasodilators: treatment of cardiac insufficiency].
Topics: Heart Failure; Humans; Hydralazine; Mitral Valve Insufficiency; Myocardial Infarction; Nitroglycerin | 1977 |
Cardiac remodeling in hypertension and following myocardial infarction: effects of arteriolar vasodilators.
Topics: Animals; Arterioles; Cardiomegaly; Extracellular Matrix; Humans; Hydralazine; Hypertension; Myocardi | 1991 |
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
Topics: Absorption; Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Platelets; Calcium Channel | 1985 |
The evolution of antihypertensive therapy.
Topics: Antihypertensive Agents; Bis-Trimethylammonium Compounds; Blood Pressure; Calcium Channel Blockers; | 1985 |
Effectiveness of drug therapy in hypertension: present status. A review.
Topics: Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Eye Diseases; Ganglionic Block | 1971 |
Genetic factors in drug therapy.
Topics: Adolescent; Aged; Alcohol Oxidoreductases; Animals; Anticoagulants; Child; Female; Glaucoma; Humans; | 1969 |
10 trials available for hydralazine and Cardiovascular Stroke
| Article | Year |
|---|---|
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr
Topics: Aged; Chronic Disease; Denmark; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; H | 2021 |
Hemodynamic trial of sequential treatment with diuretic, vasodilator, and positive inotropic drugs in left ventricular failure following acute myocardial infarction.
Topics: Adrenergic beta-Agonists; Adult; Cardiotonic Agents; Drug Therapy, Combination; Furosemide; Heart Fa | 1984 |
Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction.
Topics: Adult; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Furosemide; Heart Failure; Heart R | 1983 |
[Peripheral vasodilator agents in cardiology].
Topics: Clinical Trials as Topic; Coronary Vessels; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocar | 1980 |
[Current state of the treatment of arterial hypertension].
Topics: Adult; Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Heart Failure; Humans; Hydralazine | 1980 |
Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study.
Topics: Aged; Captopril; Coronary Disease; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Hu | 1982 |
Partial versus complete control of blood pressure in the prevention of hypertensive complications.
Topics: Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Follow-Up St | 1975 |
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
Topics: Absorption; Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Platelets; Calcium Channel | 1985 |
First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function.
Topics: Adult; Aged; Clinical Trials as Topic; Diuretics; Furosemide; Heart Ventricles; Hemodynamics; Humans | 1987 |
Appraisal of antihypertensive drug therapy.
Topics: Antihypertensive Agents; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Diabetes Comp | 1974 |
45 other studies available for hydralazine and Cardiovascular Stroke
| Article | Year |
|---|---|
Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission.
Topics: Animals; Antioxidants; Apoptosis; Disease Models, Animal; Dynamins; Enzyme Inhibitors; Female; HeLa | 2022 |
Hydralazine reduces myocardial infarct size.
Topics: Humans; Hydralazine; Myocardial Infarction | 2021 |
Electrocardiographic Changes Following Acute Hydralazine Overdose.
Topics: Adult; Antihypertensive Agents; Drug Overdose; Electrocardiography; Female; Humans; Hydralazine; Myo | 2019 |
Inhibition of semicarbazide-sensitive amine oxidase attenuates myocardial ischemia-reperfusion injury in an in vivo rat model.
Topics: Amine Oxidase (Copper-Containing); Animals; Blood Pressure; Chromatography, High Pressure Liquid; Di | 2011 |
Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study.
Topics: Animals; Disease Models, Animal; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnet | 2002 |
[HYPERTENSION].
Topics: Cerebral Hemorrhage; Diuretics; Ganglionic Blockers; Heart Arrest; Hydralazine; Hypertension; Kidney | 1963 |
Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats.
Topics: Animals; Cicatrix; Collagen; Hydralazine; Losartan; Male; Myocardial Infarction; Myocardium; Organ S | 2003 |
Increased infarct size in uremic rats: reduced ischemia tolerance?
Topics: Animals; Body Weight; Coronary Vessels; Heart Ventricles; Hydralazine; Imidazoles; Ischemia; Male; M | 2004 |
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cause of Death; Diuresi | 2005 |
ANG II type 1A receptor signaling causes unfavorable scar dynamics in the postinfarct heart.
Topics: Androstadienes; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Cell Proliferation; Fib | 2007 |
Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling.
Topics: Amlodipine; Animals; Apoptosis; bcl-Associated Death Protein; Calcineurin; Calcineurin Inhibitors; C | 2007 |
Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrasentan; Blotting | 2008 |
Electrophysiologic properties of hydralazine in man.
Topics: Aged; Bundle of His; Electrophysiology; Female; Heart Conduction System; Heart Diseases; Heart Failu | 1980 |
Vasodilator therapy for acute myocardial infarction and chronic congestive heart failure.
Topics: Captopril; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Infarction; Prazosin; Region | 1983 |
Changes in plasma renin activity and haemodynamics during vasodilator therapy in conscious dogs with myocardial infarction or chronic volume overload.
Topics: Animals; Dogs; Heart Failure; Heart Rate; Hemodynamics; Hydralazine; Kinetics; Myocardial Infarction | 1983 |
Nitrates in acute myocardial infarction.
Topics: Blood Pressure; Cardiac Output; Drug Interactions; Furosemide; Heart Failure; Heart Rate; Humans; Hy | 1984 |
The role of vasodilator therapy in the management of the patient with acute myocardial infarction.
Topics: Heart Failure; Heart Rupture; Hemodynamics; Humans; Hydralazine; Mitral Valve Insufficiency; Myocard | 1981 |
Some wrong-way chemical changes during antihypertensive treatment: comparison of indapamide and related agents.
Topics: Adult; Antihypertensive Agents; Chemical Phenomena; Chemistry; Chlorthalidone; Diuretics; Humans; Hy | 1983 |
Captopril in severe treatment-resistant hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Captopril; Female; Furosemide; Heart Rate; Humans; Hydralaz | 1980 |
Changes in control of renin release in congestive heart failure in dogs: response to acute and chronic vasodilator therapy.
Topics: Animals; Blood Pressure; Blood Volume; Dogs; Heart Failure; Heart Rate; Hydralazine; Myocardial Infa | 1982 |
Results of long-term vasodilator therapy in patients with refractory congestive heart failure.
Topics: Administration, Oral; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydralazine; I | 1981 |
The inflamed heart: pericarditis in the elderly.
Topics: Aged; Cardiac Tamponade; Daunorubicin; Echocardiography; Heart Neoplasms; Humans; Hydralazine; Myoca | 1980 |
Selective afterload reduction in the treatment of septal rupture complicating myocardial infarction. A case report.
Topics: Female; Heart Septal Defects, Ventricular; Humans; Hydralazine; Middle Aged; Myocardial Infarction; | 1980 |
Post carotid endarterectomy hypertension.
Topics: Aged; Brain Edema; Carotid Arteries; Endarterectomy; Female; Humans; Hydralazine; Hypertension; Intr | 1980 |
Changes in collagen content in the residual myocardium surviving after infarction in rats. Influence of propranolol or hydralazine therapy.
Topics: Animals; Collagen; Hydralazine; Male; Myocardial Infarction; Myocardium; Propranolol; Rats; Rats, Wi | 1995 |
Effect of bimakalim (EMD 52692), an opener of ATP sensitive potassium channels, on infarct size, coronary blood flow, regional wall function, and oxygen consumption in swine.
Topics: Animals; Benzopyrans; Coronary Circulation; Dihydropyridines; Heart; Hydralazine; Ion Channel Gating | 1994 |
Acute myocardial infarction in patients treated for hypertension in the Skaraborg Hypertension Project.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzothiadiazines; Case-Control Studies; Diuretics; Drug T | 1993 |
Nitric oxide deficiency induces myocardial infarction in hypercholesterolaemic stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cerebrovascular Disorders; Coronary Vessels; Enzyme Inhibitors; Fibrosis; H | 1997 |
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pac | 1998 |
Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Collagen; Electric Stimulation; Heart R | 1998 |
Reduction by ATP-sensitive potassium channel opener, YM934, of experimental myocardial infarct size in anesthetized dogs.
Topics: Animals; Benzoxazines; Calcium Channel Blockers; Coronary Vessels; Cyclic N-Oxides; Dogs; Drug Evalu | 1999 |
Effect of treatment of hypertension in the primary preventive trial, Göteborg, Sweden.
Topics: Adrenergic beta-Antagonists; Bethanidine; Cardiovascular Diseases; Cerebrovascular Disorders; Corona | 1979 |
[New nitrate indications].
Topics: Dihydralazine; Drug Combinations; Heart Diseases; Humans; Hydralazine; Isosorbide Dinitrate; Myocard | 1978 |
Chronic oral vasodilator therapy to control heart failure in postinfarction ventricular septal defect.
Topics: Administration, Oral; Aged; Drug Therapy, Combination; Female; Heart Failure; Heart Rupture; Heart S | 1979 |
Vasodilator and inotropic therapy of heart failure [panel discussion].
Topics: Animals; Cardiac Output; Coronary Circulation; Dobutamine; Dogs; Dose-Response Relationship, Drug; H | 1978 |
Treatment of accelerated hypertension and end stage renal failure by bilateral nephrectomy and renal transplantation.
Topics: Acute Kidney Injury; Adult; Biopsy; Blood Pressure; Child; Creatinine; Female; Graft Rejection; Guan | 1975 |
Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, | 1992 |
DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril.
Topics: Animals; Captopril; Coronary Vessels; DNA; Hydralazine; Male; Myocardial Infarction; Myocardium; Rat | 1991 |
Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine.
Topics: Animals; Blood Volume; Captopril; Chronic Disease; Heart; Heart Ventricles; Hydralazine; Male; Myoca | 1989 |
Acute effects of hydralazine and enalapril on contractile function of postischemic "stunned" myocardium.
Topics: Animals; Dogs; Enalapril; Hemodynamics; Hydralazine; Myocardial Contraction; Myocardial Infarction; | 1987 |
Current indications for vasodilator therapy for left ventricular failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Hemodynamics; Hu | 1985 |
[Effect of digoxin, apressin and nitrosorbide on the hemodynamics in patients after myocardial infarction].
Topics: Adult; Aged; Digoxin; Ferricyanides; Hemodynamics; Humans; Hydralazine; Male; Middle Aged; Myocardia | 1986 |
[Peripheral vasodilator in cardiac insufficiency in the acute period of myocardial infarction].
Topics: Cardiomyopathy, Dilated; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine | 1985 |
Results of treatment of hypertension.
Topics: Acute Kidney Injury; Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Female; Hum | 1971 |
Hypertension: challenge in preventive medicine.
Topics: Aged; Aneurysm; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therap | 1973 |